Browsing Tag
TACTI-004
3 posts
Immutep shares surge 27% as efti strategy narrows after TACTI-004 failure
Immutep Limited is narrowing eftilagimod alfa development to two oncology settings and returning to 200-litre manufacturing after finding structural differences between the material used in failed Phase III TACTI-004 and earlier successful studies.
Immutep (NASDAQ: IMMP) jumps 15% as efti review points to manufacturing differences
Immutep has identified potentially relevant structural differences between 200-litre and 2,000-litre efti manufacturing batches after the TACTI-004 failure, prompting a return to 200-litre production and a narrower clinical strategy.
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.